Literature DB >> 11220255

[Danaparoid (Orgaran) as an antiocoagulant for mechanical autotransfusion with Cell Saver 5 (Hemonetics)].

U von Lüpke1, A Marx, R Tessmann, E Lindhoff-Last.   

Abstract

We investigated Danaparoid Sodium (Orgaran) as anticoagulant using three different concentrations (9, 4,5 or 3 U/ml anticoagulant solution) for the use in the autotransfusion device Cell Saver 5 (Haemonetics). Fresh units of whole blood packs were mixed in the reservoir in a proportion of 5:1 with the anticoagulant solution. Having started the Cell Saver 5 in the automatic mode, the amount of Danaparoid in the retransfusion blood was determined (chromogenic Antifactor-Xa test). The lowest concentration of the anticoagulant was applied in 4 patients with Heparin-induced Thrombocytopenia Type II undergoing total hip arthroplasty. There was a correlation between the concentration in the reservoir and in the retransfusion blood. None of the patients showed a disturbance of his coagulation system. One of them had slight clotting in the reservoir. We recommend the use of the lower concentrations tested: 4,5 U/ml or, particularly for patients with renal insufficiency or low body weight or expected high retransfusion volumes, 3 U/ml as anticoagulant concentrations. If the autotransfusion device is used according to the manufacturer's instructions there may be virtually no risk of clotting in the Cell Saver or of inhibition of the coagulation system in the patient.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11220255     DOI: 10.1007/s001010050959

Source DB:  PubMed          Journal:  Anaesthesist        ISSN: 0003-2417            Impact factor:   1.041


  2 in total

1.  Modification of plasma glycosaminoglycans in long distance runners.

Authors:  M Contini; S Pacini; L Ibba-Manneschi; V Boddi; M Ruggiero; G Liguri; M Gulisano; C Catini
Journal:  Br J Sports Med       Date:  2004-04       Impact factor: 13.800

2.  Argatroban for anticoagulation of a blood salvage system - an ex-vivo study.

Authors:  Martin Beiderlinden; Carsten Brau; Santo di Grazia; Michael Wehmeier; Tanja A Treschan
Journal:  BMC Anesthesiol       Date:  2016-07-15       Impact factor: 2.217

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.